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Abstract
Objective To study the association of clarithromycin with cardiovascular
events in the setting of acute exacerbations of chronic obstructive
pulmonary disease and community acquired pneumonia.
Design Analysis of two prospectively collected datasets.
SettingChronic obstructive pulmonary disease dataset including patients
admitted to one of 12 hospitals around the United Kingdom between
2009 and 2011; Edinburgh pneumonia study cohort including patients
admitted to NHS Lothian Hospitals between 2005 and 2009.
Population 1343 patients admitted to hospital with acute exacerbations
of chronic obstructive pulmonary disease and 1631 patients admitted
with community acquired pneumonia.
Main outcome measures Hazard ratios for cardiovascular events at
one year (defined as hospital admissions with acute coronary syndrome,
decompensated cardiac failure, serious arrhythmia, or sudden cardiac
death) and admissions for acute coronary syndrome (acute ST elevation
myocardial infarction, non-ST elevation myocardial infarction, and
unstable angina). Secondary outcomeswere all cause and cardiovascular
mortality at one year.
Results 268 cardiovascular events occurred in the acute exacerbations
of chronic obstructive pulmonary disease cohort and 171 in the
community acquired pneumonia cohort over one year. After multivariable
adjustment, clarithromycin use in acute exacerbations of chronic
obstructive pulmonary disease was associated with an increased risk
of cardiovascular events and acute coronary syndrome—hazard ratios
1.50 (95% confidence interval 1.13 to 1.97) and 1.67 (1.04 to 2.68). After
multivariable adjustment, clarithromycin use in community acquired
pneumonia was associated with increased risk of cardiovascular events
(hazard ratio 1.68, 1.18 to 2.38) but not acute coronary syndrome (1.65,
0.97 to 2.80). The association between clarithromycin use and
cardiovascular events persisted after matching for the propensity to
receive clarithromycin. A significant association was found between
clarithromycin use and cardiovascular mortality (adjusted hazard ratio
1.52, 1.02 to 2.26) but not all cause mortality (1.16, 0.90 to 1.51) in acute
exacerbations of chronic obstructive pulmonary disease. No association
was found between clarithromycin use in community acquired pneumonia
and all cause mortality or cardiovascular mortality. Longer durations of
clarithromycin use were associated with more cardiovascular events.
Use of β lactam antibiotics or doxycycline was not associated with
increased cardiovascular events in patients with acute exacerbations of
chronic obstructive pulmonary disease, suggesting an effect specific to
clarithromycin.
Conclusions The use of clarithromycin in the setting of acute
exacerbations of chronic obstructive pulmonary disease or community
acquired pneumonia may be associated with increased cardiovascular
events. These findings require confirmation in other datasets.
Introduction
Acute exacerbations of chronic obstructive pulmonary disease
and community acquired pneumonia are two of the most
frequent causes of admission to hospital in the United Kingdom.1
Antibiotics, including clarithromycin, are commonly prescribed
during acute exacerbations of chronic obstructive pulmonary
disease, especially in the presence of increased breathlessness,
sputum volume, and purulence.2However, their widespread use
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remains controversial as the same bacteria are often found both
during exacerbations and while patients are in a stable clinical
state, and proving a causative role is difficult.3 Furthermore,
triggers other than bacterial infection, such as viruses and
environmental factors, may be responsible for an important
proportion of acute exacerbations.4
Use of macrolide antibiotics in community acquired pneumonia
has been consistently associated with improved short term
mortality in observational studies,5 6 and national and
international guidelines therefore recommend their use in
combination with β lactams for patients admitted to hospital.7 8
The improvement in short term mortality has been attributed to
empirical coverage of atypical bacterial pathogens, but data
suggesting improved outcomes with combinations of β lactams
and macrolides for pneumococcal pneumonia have also been
reported.9 Consequently, macrolides are recommended for all
patients withmoderate to severe community acquired pneumonia
and for patients with mild pneumonia intolerant of β lactams.7
Widespread use of macrolide antibiotics has been accompanied
by concerns about their possible deleterious effects on
cardiovascular morbidity and mortality. Although initial pilot
studies suggested that short term use of macrolides may have
advantageous effects on cardiovascular outcomes,10 11 a
subsequent retrospective study of erythromycin use in 1 249
943 patients identified a significant increase in deaths from
cardiovascular disease.12Another macrolide, azithromycin, was
shown to have a similar association with increased
cardiovascular deaths during the time of administration.13
CLARICOR (Effect of Clarithromycin on Mortality and
Morbidity in Patients with Ischemic Heart Disease trial) was a
double blind, placebo controlled trial showing that a two week
course of clarithromycin significantly increased cardiovascular
and all cause mortality in patients with coronary heart disease
but no evidence of respiratory infection.14 This finding was
remarkable because the increased mortality rate persisted for
three years after discontinuation of the drug. These findings
were consolidated in a recent meta-analysis of 17 trials of
antibiotics in coronary heart disease that showed increased long
term mortality after macrolides, primarily due to increased
deaths from cardiovascular disease.15
Clarithromycin is the most frequently used macrolide in the
UK.16 No studies have examined the long term effect of
clarithromycin on cardiovascular events andmortality in patients
after acute exacerbations of chronic obstructive pulmonary
disease or community acquired pneumonia.
We analysed data from two large prospective cohort studies in
patients to hospital with acute exacerbations of chronic
obstructive pulmonary disease and community acquired
pneumonia. We hypothesised that use of clarithromycin would
be associated with excess cardiovascular events and mortality
beyond the time of prescription.
Methods
Study populations
This paper describes a secondary analysis of two large
prospectively collected datasets. These were a multicentre
observational study of patients admitted to hospital with
exacerbations of chronic obstructive pulmonary disease and the
Edinburgh pneumonia study cohort.
Exacerbation of chronic obstructive pulmonary
disease study
The EXODUS (Exacerbations of Obstructive Lung Disease
managed in UK Secondary care) dataset consists of patients
over the age of 40 years admitted to one of 12 hospitals around
the UK with acute exacerbations of chronic obstructive
pulmonary disease between 2009 and 2011. Patients with a
previous diagnosis of chronic obstructive pulmonary disease
confirmed by spirometry were included if they were admitted
to hospital with a primary diagnosis of an acute exacerbation.
Patients with other respiratory conditions (active thoracic
malignancy, asthma, and interstitial lung disease), those already
on long termmacrolide treatment, and those treated with primary
palliative intent were excluded. Baseline patient demographics,
severity of chronic obstructive pulmonary disease defined by
spirometry, Medical Research Council dyspnoea score, and
bodymass index were recorded, as well as features and severity
of exacerbation, treatment including antibiotic choice, and
outcome of exacerbation.
We used national death certification data to identify all deaths
and those for which a cardiovascular cause of death was
recorded. We identified cardiovascular related hospital
admissions when an ICD-10 (international classification of
diseases, 10th revision) code denoting cardiovascular disease
was used to record the cause of admission. The ICD-10 codes
were I20-23 (acute myocardial infarction and acute coronary
syndromes including unstable angina), I50 (cardiac failure
incorporating congestive cardiac failure (I.50.0) and left
ventricular failure (I50.1)), I46 (cardiac arrest), and cardiac
arrhythmia (I44 (atrioventricular disorders), I45 (other
conduction disorders), I47 (paroxysmal tachycardia), I48 (atrial
fibrillation and flutter), I49 (other cardiac arrhythmias)). These
codes do not include sinus bradycardia or sinus tachycardia as
an arrhythmia.
Edinburgh pneumonia study cohort
The Edinburgh pneumonia cohort has been described
elsewhere17; this study enrolled consecutive unselected patients
admitted with radiologically confirmed community acquired
pneumonia to NHS Lothian Hospitals in Edinburgh, UK,
between 2005 and 2009. Patients were included in the study if
they presented with a new infiltrate on a chest radiograph and
had three or more of the following symptoms or signs: cough,
sputum production, breathlessness, pleuritic chest pain,
haemoptysis, fever, headache, and signs consistent with
pneumonia on chest auscultation. Exclusion criteria were
hospital acquired pneumonia (development of symptoms >48
hours after admission to or discharge from an acute care facility
less than two weeks before admission), active malignancy,
immunosuppression (including HIV infection and use of long
term oral steroids or other forms of immunosuppressant
treatment), pulmonary embolism, tuberculosis, and patients
already on long term macrolide treatment or in whom active
treatment was not considered appropriate (palliative care).
Two independent reviewers reviewed patients’ case notes to
determine the presence of cardiovascular events and classified
the cause of death as cardiovascular or non-cardiovascular.
Disagreements were resolved by discussion. Cardiovascular
events were defined as hospital admissions or emergency
department attendances with one of ST elevation myocardial
infarct, non-ST elevation myocardial infarction, new or
worsening congestive cardiac failure, new arrhythmia, or out
of hospital cardiac arrest.
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Outcome
The primary outcome was the association between
clarithromycin use and the first hospital admission due to a
cardiovascular event or acute coronary syndrome (acute ST
elevation myocardial infarction, non-ST elevation myocardial
infarction, and unstable angina) within one year. Secondary
outcomes were cardiovascular mortality and all cause mortality
at one year.
Clarithromycin use
We classified all patients who received at least one dose of
clarithromycin during their hospital admission as macrolide
users. We compared themwith patients who did not receive any
macrolide antibiotics during their admission.
Data analysis
We used SPSS version 21 for statistical analyses. For propensity
matching, we used the propensity matching add-on for SPSS
(SPSS essentials for R and R version 2.14.2).
Cox proportional hazards regression
We used Cox proportional hazards regression to calculate crude
and adjusted hazard ratios for all analyses of clarithromycin use
with outcomes. We present data as adjusted hazard ratios with
95% confidence intervals and as Cox survival curves for the
primary outcome. We calculated adjusted hazard ratios after
multivariable correction for age, sex, history of cardiovascular
disease (previous myocardial infarction, stable angina, or
coronary artery bypass grafting), previous cerebrovascular
disease (stroke or transient ischaemic attack), neoplastic disease,
diabetes mellitus, smoking, and use of cardiac drugs (antiplatelet
agents, statins, angiotensin converting enzyme inhibitors,
angiotensin II receptor blockers, calcium channel antagonists,
and β blockers). Severity of illness is associated with
cardiovascular events and long term mortality, so we adjusted
for it in all models by using validated severity scores: BAP-65
(elevated blood urea, altered mental status, pulse >109, and age
>65 years) in the chronic obstructive pulmonary disease
analysis,18 and the pneumonia severity index in the community
acquired pneumonia analysis.19 In addition, we adjusted for
baseline severity of chronic obstructive pulmonary disease by
entering per cent predicted forced expiratory volume in one
second, pre-morbid MRC dyspnoea score, body mass index,
and use of long term oxygen therapy into the chronic obstructive
pulmonary diseasemodels.We also adjusted chronic obstructive
pulmonary disease models for use of inhaled corticosteroid,
long acting β agonist, and long acting anti-muscarinic drugs.
The community acquired pneumonia analysis adjusted for
requirement for mechanical ventilation or vasopressor support.
As both studies included patients from more than one hospital,
we included hospital as an independent variable to account for
possible differences in macrolide use between hospitals. We
entered the presence of chronic obstructive pulmonary disease
as an independent variable in the community acquired
pneumonia analysis. All models used forced entry of all
available covariates to minimise residual confounding.
Propensity adjusted analysis
We used multivariable logistic regression to assess the
probability that a patient would receive clarithromycin. The
variables included in the propensity model were all those
included in the Coxmodel in addition to admission temperature,
acidosis, white blood cell count, and pre-admission antibiotic
treatment in both cohorts. Specific variables were only available
for adjustment in each individual cohort. In the acute
exacerbations of chronic obstructive pulmonary disease cohort,
these were admission symptoms (cough, increased sputum,
sputum colour, chest pain), history of exacerbations in the
previous year, and requirement for bilevel ventilation. The
community acquired pneumonia analysis was also adjusted for
intensive care unit admission, suspected aspiration, and Eastern
Co-operative Oncology Group performance status.20
We assessed multicollinearity by using bivariate linear
regression between variables and using the variance inflation
factor. We regarded a variance inflation factor of less than 2.5
as excluding significant interactions.
We used this multivariable model to create a propensity score
for each patient, representing the probability that an individual
patient would be treated with clarithromycin. We then matched
each patient treated with clarithromycin to a patient treated with
other antibiotics with a similar propensity score by using greedy
matching. This created two cohorts that were well matched for
measured confounders (see supplementary data for the
characteristics of the matched cohorts). As a sensitivity analysis
to exclude strong differential effects among patients who could
not be matched, we also repeated the analysis including the
propensity score as a covariate in the Cox proportional hazards
regression.
Missing data
We used multiple imputation to account for missing values in
each database.We performed and report the multiple imputation
analysis according to the recommendations of Sterne et al.21We
did the analysis by using the multiple imputation function in
SPSS version 21. The imputation model included all variables
included in the propensity analysis for both the cohorts (these
models also included the variables included in the Cox
regression models). No data were missing for clarithromycin
prescriptions or for the outcomes. We present analyses for five
imputed models, as recommended by Sterne et al,21 with a
sensitivity analysis showing an analysis of data from cases with
complete data only.
Sensitivity analysis
To assess the influence of duration of antibiotic treatment, we
analysed the association of clarithromycin use with
cardiovascular outcomes according to the length of treatment
(<3 days, 3-6 days, 7 days, and >7 days).We did further analyses
including only events occurring after 14 days and while patients
were on and off treatment, to minimise immortal time bias.22 In
addition, we did subgroup analyses stratifying patients according
to their baseline cardiovascular risk.We used the QRISK2 score
to estimate cardiovascular risk in patients without established
cardiovascular disease. We calculated this as previously
described, incorporating age, sex, smoking status, diabetes,
family history, medical treatment, deprivation index, bodymass
index, systolic blood pressure, cholesterol, ethnicity, and
comorbidities.23We regarded a 10 year cardiovascular risk above
20% as high risk. To assess the influence of patients’ age, we
analysed the association of clarithromycin use on cardiovascular
outcomes according thirds of age in the two cohorts. We tested
for interaction of these potential effect modifiers as described
by Altman et al.24
We also did sub-analyses in the groups receiving statins and
other cardiovascular drugs on the basis of the CLARICOR data
suggesting that cardiovascular drugs, particularly statins,25 could
prevent the excess cardiovascular events associated with
clarithromycin. We analysed the association of β lactams and
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doxycycline with cardiovascular events in the chronic
obstructive pulmonary disease cohort to ensure that any signal
seen was specific to clarithromycin. We calculated the number
needed to harm from the hazard ratio, as described by Altman
et al.26 For all tests, we considered a two sided P value of less
than 0.05 to be statistically significant.
Results
The EXODUS dataset included 1343 patients, and the
community acquired pneumonia cohort had 1631 patients; table
1⇓ shows their baseline characteristics. Severity measured by
BAP-65 differed significantly between clarithromycin users and
non-users in the chronic obstructive pulmonary disease cohort,
but other severity markers and demographics were similar.
Significant baseline disparities existed between clarithromycin
users and non-users in the community acquired pneumonia
cohort.
Clarithromycin use and cardiovascular events
During one year of follow-up, 268 patients from the chronic
obstructive pulmonary disease cohort and 171 from the
community acquired pneumonia cohort were admitted to hospital
as a result of a cardiovascular event. Table 2⇓ shows the nature
of these events in patients treated with clarithromycin and
patients not treated with clarithromycin. Figures 1⇓ and 2⇓ show
Cox adjusted survival curves for cardiovascular events in the
two cohorts.
Acute exacerbations of chronic obstructive
pulmonary disease cohort
The unadjusted hazard ratio for the association of clarithromycin
with cardiovascular events in the chronic obstructive pulmonary
disease cohort was 1.48 (95% confidence interval 1.13 to 1.94).
For acute coronary syndrome, the unadjusted hazard ratio was
1.46 (0.93 to 2.29). In the multivariable analysis, clarithromycin
use was associated with increased risk of cardiovascular events
(hazard ratio 1.50, 1.13 to 1.97) and acute coronary syndrome
(1.67, 1.04 to 2.68).
Community acquired pneumonia cohort
In the unadjusted analysis, clarithromycin was associated with
cardiovascular events (hazard ratio 1.75, 1.25 to 2.45) and with
acute coronary syndrome (1.81, 1.08 to 3.02) in the community
acquired pneumonia cohort. After adjustment for confounders
in the Cox proportional hazards model, clarithromycin use was
associated with an increased risk of cardiovascular events
(hazard ratio 1.68, 1.18 to 2.38), but the association with acute
coronary syndrome was no longer statistically significant (1.65,
0.97 to 2.80).
Propensity adjusted analysis
The relation between clarithromycin use in acute exacerbations
of chronic obstructive pulmonary disease and cardiovascular
events persisted after propensity matching (hazard ratio 1.48,
1.02 to 2.14). We also found significant association between
clarithromycin use and cardiovascular events in the community
acquired pneumonia cohort after propensity matching (hazard
ratio 1.58, 1.08 to 2.30). Incorporating the propensity score into
the Cox model gave similar results for acute exacerbations of
chronic obstructive pulmonary disease (1.50, 1.13 to 1.98) and
community acquired pneumonia (1.59, 1.10 to 2.29). The
characteristics of the cohorts produced after propensity matched
are shown in the supplementary data.
Cardiovascular and all cause mortality
Inpatient mortality during acute exacerbations of chronic
obstructive pulmonary disease was 6.2%, and 18.8% of patients
who survived to discharge died during one year’s post-discharge
follow-up had died by one year. Inpatient mortality in the
community acquired pneumonia cohort was 8.7%, and 12.8%
of those who survived to discharge died during one year’s
post-discharge follow-up. Cardiovascular mortality at one year
was 10.2% after acute exacerbations of chronic obstructive
pulmonary disease and 4.4% in the community acquired
pneumonia cohort.
In the chronic obstructive pulmonary disease cohort, we found
a significant association between clarithromycin use and
cardiovascular mortality (unadjusted hazard ratio 1.53, 1.05 to
2.23; adjusted hazard ratio 1.52, 1.02 to 2.26) but no association
with all cause mortality (unadjusted hazard ratio 1.15, 0.89 to
1.48; adjusted hazard ratio 1.16, 0.90 to 1.51).
Clarithromycin use in community acquired pneumonia was not
associated with a significant difference in all cause mortality
(unadjusted hazard ratio 1.22, 0.92 to 1.62; adjusted hazard ratio
1.13, 0.85 to 1.51) or cardiovascular mortality (unadjusted
hazard ratio 1.71, 1.02 to 2.87; adjusted hazard ratio 1.58, 0.93
to 2.71).
Timing of cardiovascular events
We found no significantly increased risk of cardiovascular
events while patients were taking clarithromycin in the chronic
obstructive pulmonary disease cohort (hazard ratio 1.73, 0.71
to 4.25), but an increased risk was present after the
clarithromycin course was ended (1.41, 1.05 to 1.89). In the
community acquired pneumonia cohort, the hazard ratio for
association between clarithromycin use and cardiovascular
events was 1.84 (0.75 to 4.51) during clarithromycin use and
1.66 (1.14 to 2.43) after the antibiotic was stopped.
Association with duration of antibiotic use
Longer courses of clarithromycin were associated with more
cardiovascular events (table 3⇓). The median duration of
treatment was seven days in both cohorts. Less than three days
of clarithromycin treatment was not associated with
cardiovascular events in the chronic obstructive pulmonary
disease cohort (hazard ratio 0.89, 0.50 to 1.57) or the community
acquired pneumonia cohort (0.63, 0.15-2.65), compared with
patients who did not receive clarithromycin. This compared
with hazard ratios of 1.73 (1.04 to 2.88) and 2.02 (1.34 to 3.04)
for durations in excess of seven days in the two cohorts.
Effect of age and cardiovascular risk status
Acute exacerbations of chronic obstructive
pulmonary disease cohort
In the chronic obstructive pulmonary disease cohort,
clarithromycin use was associated with a significantly increased
risk of cardiovascular events in patients with a previous history
of cardiovascular disease (hazard ratio 1.69, 1.07 to 2.67). We
stratified patients without a history of cardiovascular disease
by their QRISK2 score. The hazard ratios of the effect of
clarithromycin on cardiovascular events in such patients were
1.35 (0.94 to 1.95) in those with a high cardiovascular risk and
0.88 (0.20 to 3.96) in those with a low risk. The tests of
interaction for these subgroups were not statistically significant
(P=0.08 and P=0.4 comparing patients with a previously history
of ischaemic heart disease with high risk and low risk patients).
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The lowest hazard ratios for cardiovascular events were in
patients aged 60 or below (1.01, 0.36 to 2.91). The hazard ratio
was 1.47 (1.01 to 2.14) for patients aged 60-79, and a higher
risk was associated with clarithromycin use in patients aged
over 80 (hazard ratio 1.68, 1.05 to 2.69). The interaction test
for age was not statistically significant (P=0.4 and P=0.7
comparing the oldest cohort with two younger cohorts).
Community acquired pneumonia cohort
In the community acquired pneumonia cohort, clarithromycin
was most strongly associated with cardiovascular events in
patients with a history of cardiovascular events (hazard ratio
1.98, 1.15 to 3.39) and in those at high risk of cardiovascular
disease (1.84, 1.01 to 3.36), with no increased events evident
in patients classified as being at low risk of ischaemic heart
disease (hazard ratio 1.08, 0.52 to 2.23) Again, the tests for
interaction were not statistically significant (P>0.05 for all
comparisons). We also analysed the association of
clarithromycin with cardiovascular events by age group, with
the lowest hazard ratio seen in patients aged 50 or below (0.88,
0.28 to 2.78). The hazard ratio was 1.57 (0.80-3.11) for patients
aged 50-69, and a higher risk was associated with clarithromycin
use in patients aged 70 or over (hazard ratio 1.81, 1.19 to 2.76).
The test of interaction was not statistically significant (P>0.05
for all analyses).
Use of other antibiotics
Use of β lactam or doxycycline was not associated with
increased cardiovascular events (hazard ratios 1.06 (0.83 to
1.37) and 0.96 (0.61 to 1.51), respectively) in the chronic
obstructive pulmonary disease cohort compared with patients
not receiving antibiotics. All patients received antibiotics in the
community acquired pneumonia cohort, so we could not repeat
this analysis in that cohort.
Use of cardiovascular drugs
We did an exploratory analysis of the risk of cardiovascular
events in clarithromycin users who were also prescribed
cardiovascular drugs. In the chronic obstructive pulmonary
disease cohort, macrolide use among statin users was associated
with a hazard ratio of 1.45 (0.81 to 2.62) compared with
non-macrolide users. The concomitant use of clarithromycin,
angiotensin converting enzyme inhibitors, and statins and of
clarithromycin, statins, angiotensin converting enzyme
inhibitors, and β blockers was associated with hazard ratios of
1.13 (0.50 to 2.54) and 0.58 (0.01 to 44.7), respectively. Tests
of interaction compared with the treatment effect in the whole
population were not statistically significant (P>0.05 for all
analyses).
Similarly, in the community acquired pneumonia cohort,
cardiovascular drugs did not significantly modify the effect of
clarithromycin on cardiovascular events (P>0.05 for all
interaction tests). Patients who used clarithromycin and a statin
had a hazard ratio of 1.40 (0.73 to 2.69), users of clarithromycin,
angiotensin converting enzyme inhibitors, and statins had a
hazard ratio of 1.37 (0.48 to 3.96), and among patients using
clarithromycin, statins, angiotensin converting enzyme
inhibitors, and β blockers, the hazard ratio was 1.32 (0.54 to
3.24).
Missing data
In the chronic obstructive pulmonary disease cohort, missing
data accounted for less than 1% of the data. Complete datasets
with no missing data in any fields were available in 84.1% of
patients. No significant differences existed in characteristics or
outcomes between patients with and without complete datasets,
and we assumed data to be missing at random. The most
frequently missing data were previous history of exacerbations
(12.1% of the cohort missing) and body mass index (12.0%);
the least frequent missing data were for temperature (three
patients, 0.2%) and white blood cell count (two patients, 0.1%).
The imputation model used did not significantly affect the
results; each model gave similar results for the association
between macrolide use and cardiovascular events in the chronic
obstructive pulmonary disease cohort—model 1: hazard ratio
1.50 (1.13 to 1.97); model 2: 1.47 (1.11 to 1.93); model 3: 1.49
(1.13 to 1.96), model 4: 1.49 (1.13 to 1.96); and model 5: 1.51
(1.14 to 1.99). In the model including only patients with
complete data, the hazard ratio for cardiovascular events was
1.51 (1.10 to 2.08). No data were missing for the variables
included in the Cox regressionmodel in the community acquired
pneumonia cohort.
Number needed to harm
For cardiovascular events in the main analysis, the number
needed to harm calculated from the hazard ratio was 8 (95%
confidence interval 5 to 24) patients for macrolide use in acute
exacerbations of chronic obstructive pulmonary disease and 11
(8 to 26) for macrolide use in community acquired pneumonia.
Discussion
This is the first study showing that use of clarithromycin in the
context of exacerbations of chronic obstructive pulmonary
disease and community acquired pneumonia may be associated
with excess cardiovascular events that last beyond the period
of prescription. Clarithromycin is the most widely used
macrolide in the UK and is strongly recommended for use in
patients with severe community acquired pneumonia. Previous
studies have suggested an excess cardiovascular morbidity after
clarithromycin use,14 but these patients were selected on the
basis of pre-existing cardiovascular risk rather than having a
defined infective episode requiring treatment with this drug.
Other studies have shown a short term association seen only
during the time of administration.12 13 The observed association
with cardiovascular events is of a similar magnitude to that seen
in stable non-infected patients with established coronary artery
disease.14 Our data suggest that the increased risk may persist
beyond the time when clarithromycin is stopped.
Possible explanations for findings
Although short term events may be associated with
clarithromycin’s pro-arrhythmic effects mediated through
prolongation of the QT interval,27 this would not affect outcome
after cessation of the drug and would support an ischaemic
mechanism. Clarithromycin may activate macrophages, leading
to an inflammatory cascade resulting in more vulnerable plaques
that over time may lead to acute coronary syndromes or sudden
cardiac death by plaque rupture.25 This may explain why
clarithromycin seems to increase cardiovascular events and
mortality beyond the time of prescription.
We did several hypothesis generating analyses to explore the
relation between clarithromycin use and cardiovascular events
in these cohorts. We found a strong association between
prolonged (more than seven days) courses of clarithromycin
and cardiovascular events, which strengthens the case for a true
biological cause. The association between duration of antibiotic
treatment and cardiovascular events could also represent residual
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confounding by severity of illness. Although prolonged courses
of antibiotics are common for respiratory tract infections in
clinical practice, a considerable body of evidence suggests that
short courses of antibiotics are equivalent to prolonged courses
in community acquired pneumonia and other respiratory tract
infections.28
Strengths and weaknesses of study
The strengths of this study are that data were collected in routine
care from unselected hospital admissions for community
acquired pneumonia or acute exacerbations of chronic
obstructive pulmonary disease throughout the UK. A similar
effect was seen in a previous randomised controlled study.14
This increases the likelihood that the results will be applicable
to other populations.
Despite data being collected prospectively according to
predefined criteria, follow-up data are observational and
therefore prone to the weaknesses of this type of study. We
attempted to limit bias and confounding by adjusting for all
measured confounders in each database, but bias due to
unrecorded factors may remain. However, the fact that the results
of the propensity score matched approach show similar hazard
ratios for cardiovascular events in both cohorts is reassuring.
Previous studies have shown that cardiovascular events are
common sequelae of respiratory infection, including chronic
obstructive pulmonary disease exacerbations and pneumonia.29 30
A potential weakness is that patients with more severe illness
were more likely to be prescribed clarithromycin and that
clarithromycin may therefore be a marker for more severe
infection, and hence increased cardiovascular events, rather than
a direct cause of cardiovascular events. We attempted to limit
this by adjusting for severity according to BAP-65 and the
pneumonia severity index and by using a propensity score.
Furthermore, this was a hospital based study and the results
cannot be extrapolated to prescribing in primary care.
Another potential weakness is that the two cohorts recruited
patients over different ranges of time. However, we do not
believe that this affects the conclusion of the study, as antibiotic
guidelines did not change appreciably over this time.
Implications of findings
Evidence is accumulating for long term cardiovascular risks
associated with macrolides.14 15 The role of antibiotics in
exacerbations of chronic obstructive pulmonary disease is
controversial,3 4 and no evidence from controlled trials suggest
that macrolides are superior to the alternatives in this situation.
As this study is observational in nature, the findings need to be
validated in other datasets before recommendations to change
practice can be made.
The role of macrolides in community acquired pneumonia is
more complex. A large body of evidence suggests that short
term mortality is reduced in patients receiving macrolides for
severe community acquired pneumonia.5 6 No large scale
randomised controlled trials have been done, and alternative
agents to cover atypical pathogens are available. Our data would
support the need for a high quality randomised controlled trial
of macrolides with long term follow-up.
An intriguing finding of this study was that prolonged courses
of clarithromycin (more than seven days) may be associated
with increased risk of cardiovascular events especially in patients
with a pre-existing history of coronary heart disease. This may
be of particular importance given recent data supporting long
term macrolide use to prevent exacerbations of chronic
obstructive pulmonary disease.31
Conclusion
The use of clarithromycin in the setting of hospital admissions
for infective exacerbations of chronic obstructive pulmonary
disease or community acquired pneumonia may be associated
with increased cardiovascular events. Our findings require
validation in independent datasets, especially from primary care
settings and through randomised controlled trials of macrolides
with long term follow-up.
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Tables
Table 1| Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Non-clarithromycin userClarithromycin userStudy cohortCharacteristics
(n=1062)(n=281)(n=1343)COPD cohort
72 (63-80)70 (63-79)72 (63-79)Median (IQR) age (years)
521 (49)134 (48)655 (49)Male sex
358 (34)90 (32)448 (33)Active smokers
305 (29)72 (26)377 (28)Previous myocardial infarction
155 (15)40 (14)195 (15)Previous stroke
85 (8)30 (11)115 (9)Renal failure
169 (16)34 (12)203 (15)Diabetes
131 (12)40 (14)171 (13)Previous neoplastic disease
101 (10)21 (7)122 (9)Prescribed long term oxygen therapy
47 (35-67)45 (35-62)46 (34-67)Median (IQR) FEV1 (% predicted)
4 (3-5)4 (3-5)4 (3-5)Median (IQR) MRC dyspnoea score
218 (21)47 (17)265 (20)Severe exacerbation: BAP65 score >2
(n=651)(n=980)(n=1631)CAP cohort
68 (53-78)65 (53-76)66 (53-77)Median (IQR) age (years)
310 (48)496 (51)806 (49)Male sex
204 (31)369 (38)573 (35)Active smokers
171 (26)235 (24)406 (25)Previous cardiovascular disease
72 (11)94 (10)166 (10)Previous stroke
30 (5)53 (5)83 (5)Liver disease
24 (4)48 (5)72 (4)Renal failure
45 (7)107 (11)152 (9)Diabetes
238 (37)489 (50)727 (45)Severe CAP: PSI >2
BAP65=elevated blood urea, altered mental status, pulse >109, and age >65 years; CAP=community acquired pneumonia; COPD=chronic obstructive pulmonary
disease; FEV1=forced expiratory volume in one second; IQR=interquartile range; MRC=Medical Research Council; PSI=pneumonia severity index.
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Table 2| Frequency of cardiovascular events in patient cohorts. Values are numbers (percentages)
CAP cohortCOPD cohort
Events
Non-clarithromycin user
(n=651)
Clarithromycin user
(n=980)
Non-clarithromycin user
(n=1062)
Clarithromycin user
(n=281)
48 (7.4)123 (12.6)195 (18.4)73 (26.0)Patients with ≥1 cardiovascular
event
9 (1.4)25 (2.6)29 (2.7)12 (4.3)Myocardial infarction
11 (1.7)29 (3.0)40 (3.8)14 (5.0)NSTEMI or acute coronary
syndrome
21 (3.2)32 (3.3)56 (5.3)32 (11.4)Congestive cardiac failure or left
ventricular failure
23 (3.5)64 (6.5)108 (10.2)47 (16.7)Arrhythmia
6 (0.9)14 (1.4)3 (0.3)2 (0.7)Cardiac arrest/sudden cardiac
death
Sum total of events may be greater than number of patients with events, as some patients had more than one cardiovascular event.
CAP=community acquired pneumonia; COPD=chronic obstructive pulmonary disease; NSTEMI=non-ST elevation myocardial infarction.
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Table 3| Effect of clarithromycin duration on cardiovascular events
Hazard ratio (95% CI) for cardiovascular events
Duration of treatment CAP cohortCOPD cohort
1.00 (reference)1.00 (reference)No clarithromycin
<3 days:
0.64 (0.16 to 2.63)0.37 (0.05 to 2.70)Unadjusted
0.63 (0.15 to 2.65)0.89 (0.50 to 1.57)Adjusted
3-6 days:
1.09 (0.43 to 2.74)0.68 (0.17 to 2.72)Unadjusted
1.05 (0.40 to 2.76)0.83 (0.20 to 3.36)Adjusted
7 days:
1.65 (1.12 to 2.43)1.47 (1.04 to 2.08)Unadjusted
1.53 (1.03 to 2.30)1.58 (1.10 to 2.26)Adjusted
>7 days:
2.09 (1.43 to 3.07)1.64 (1.12 to 2.39)Unadjusted
2.02 (1.34 to 3.04)1.73 (1.04 to 2.88)Adjusted
CAP=community acquired pneumonia; COPD=chronic obstructive pulmonary disease.
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Figures
Fig 1 Cox adjusted survival curves for cardiovascular events in acute exacerbations of chronic obstructive pulmonary
disease cohort
Fig 2 Cox adjusted survival curves for cardiovascular events in community acquired pneumonia cohort
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